Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 8/20 | 0.59 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.56 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598686 | 1.00 | CYP26A1 (0.59) | CYP26A1CYP24A1CYP19A1CYP27A1ITGB3 | |
| SCHEMBL9419768 | 0.77 | CA12 (0.43) | CYP26A1CYP24A1CYP19A1CYP27A1THRA | |
| SCHEMBL20809845 | 0.77 | CYP26A1 (0.47) | CYP26A1CYP24A1CYP19A1CYP27A1ITGB3 | |
| SCHEMBL10450802 | 0.74 | CA12 (0.43) | CYP26A1CYP24A1CYP19A1CYP27A1THRA | |
| SCHEMBL7245357 | 0.73 | CYP24A1 (0.80) | CYP26A1CYP24A1CYP19A1CYP27A1 | |
| SCHEMBL6827615 | 0.72 | CYP19A1 (1.00) | CYP26A1CYP24A1CYP19A1CYP27A1 | |
| SCHEMBL8159828 | 0.72 | CYP26A1 (0.78) | CYP26A1CYP24A1CYP19A1CYP27A1 | |
| SCHEMBL6113027 | 0.71 | MAOB (0.50) | — | |
| SCHEMBL8203668 | 0.70 | CYP26A1 (0.79) | CYP26A1CYP24A1CYP19A1CYP27A1ITGB3 | |
| SCHEMBL24529065 | 0.70 | MAOB (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111183130-B | Benzoheterocycle derivatives and pharmaceutical compositions containing the same | 恒翼生物医药(上海)股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2021-08-17 | — | — | US | disclosed |
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2021-08-17 | — | — | US | disclosed |
| EP-3679012-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Taiwanj Pharmaceuticals Co., Ltd. (TW) | 2020-07-15 | — | — | EP | disclosed |
| US-20200190010-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2020-06-18 | — | — | US | disclosed |
| US-20200190010-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2020-06-18 | — | — | US | disclosed |
| CN-111183130-A | Benzoheterocyclic derivatives and pharmaceutical compositions containing the same | 景凱生物科技股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2019051222-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051222-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | RORB, RORC, NR3C1 | CYP26A1 418/4885CYP24A1 262/4885CYP19A1 224/4885 |
| US-20200190010-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | RORB, RORC, NR3C1 | CYP26A1 418/4885CYP24A1 262/4885CYP19A1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.